These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10170205)

  • 21. McClellan moves on, sets sights on drug reimbursement.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):366. PubMed ID: 15060537
    [No Abstract]   [Full Text] [Related]  

  • 22. Formulary management of biotechnological drugs.
    Herfindal ET
    Am J Hosp Pharm; 1989 Dec; 46(12):2516-20. PubMed ID: 2603888
    [No Abstract]   [Full Text] [Related]  

  • 23. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
    Dalzell MD
    Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
    [No Abstract]   [Full Text] [Related]  

  • 24. Maximizing IT in smaller hospitals. Benefits of combined clinical information and cost accounting systems exceed those of either one alone.
    Reynolds J; Rabin J
    Healthc Inform; 2004 May; 21(5):49-52. PubMed ID: 15179739
    [No Abstract]   [Full Text] [Related]  

  • 25. Formulary decision-making considerations: COX-2 inhibitors.
    Shaya FT; Wong W; Shin JY; Martin L; Samant N
    Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
    Weeks EA
    Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
    [No Abstract]   [Full Text] [Related]  

  • 27. Europeans outraged over expanded access.
    Alcorn K; Nary G; Pernet AG; Surchio JL; Weiner JD
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):48-51. PubMed ID: 11363519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP
    Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug information resources for health professionals and consumers.
    Durkin C
    Natl Netw; 1998 Feb; 22(3):10-1. PubMed ID: 10176590
    [No Abstract]   [Full Text] [Related]  

  • 30. How one award team makes its decisions.
    Hosp Peer Rev; 1999 May; 24(5):77-9. PubMed ID: 10623129
    [No Abstract]   [Full Text] [Related]  

  • 31. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 34. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 35. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 36. Developing business opportunities in a provider-sponsored organization.
    Allen B; Sharar D
    Behav Healthc Tomorrow; 1999 Apr; 8(2):45-7, 50. PubMed ID: 10351301
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 39. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.